Document Detail

Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
MedLine Citation:
PMID:  20550538     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson's disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy.
DESIGN: Cross-sectional, two-dimensional echocardiographic study performed by a single echocardiographer.
PATIENTS: Seventy-two patients (median age 36 years, 19 men) receiving cabergoline for hyperprolactinaemia, and 72 controls prospectively matched for age, sex and cardiovascular risk factors. Measurements Assessment of valvular mobility, regurgitation and morphology.
RESULTS: Median cumulative dose exposure for cabergoline was 126 (58-258) mg, and patients had received cabergoline for 53 (26-96) months. The frequency of mild mitral regurgitation was identical (5/72, 7%) in patient and control groups. Mild aortic regurgitation was not significantly different between groups (4/72 [controls] vs 2/72 [patients], P = 0.681). There was only one case of tricuspid regurgitation, which was mild and observed in a cabergoline-treated patient. Nodular thickening of the right coronary cusp, noncoronary cusp or left coronary cusp of the aortic valve was observed at a similar frequency in both groups. There were no cases of extensive thickening of any valvular leaflet.
CONCLUSION: Our data demonstrates that there is no association between cabergoline treatment for hyperprolactinaemia and valvulopathy. This study therefore supports continued use of low-dose cabergoline for patients with hyperprolactinaemia.
Tricia Tan; Ines Z Cabrita; Davina Hensman; Joanna Grogono; Waljit S Dhillo; Kevin C Baynes; Joseph Eliahoo; Karim Meeran; Stephen Robinson; Petros Nihoyannopoulos; Niamh M Martin
Related Documents :
9766588 - Long-term doppler echocardiographic results of aortic or mitral valve replacement with ...
8853128 - Risks for and prevention of infective endocarditis.
6179198 - Surgical treatment of various types of left ventricular outflow tract stenosis by aorto...
17478158 - Aortic arch geometry and exercise-induced hypertension in aortic coarctation.
24315768 - Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients.
9786318 - Oral mucosal changes in coeliac patients on a gluten-free diet.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-09
Journal Detail:
Title:  Clinical endocrinology     Volume:  73     ISSN:  1365-2265     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-27     Completed Date:  2011-02-28     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  369-74     Citation Subset:  IM    
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiparkinson Agents / adverse effects,  therapeutic use
Blood Pressure
Cross-Sectional Studies
Dose-Response Relationship, Drug
Ergolines / adverse effects,  therapeutic use*
Heart Valve Diseases / chemically induced,  diagnosis,  physiopathology*
Heart Valves / drug effects,  physiopathology*,  ultrasonography
Hyperprolactinemia / drug therapy*
Middle Aged
Prospective Studies
Risk Assessment / methods
Ventricular Function, Left
Ventricular Function, Right
Reg. No./Substance:
0/Antiparkinson Agents; 0/Ergolines; LL60K9J05T/cabergoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relationships between dimethylarginine and the presence of vertebral fractures in type 2 diabetes me...
Next Document:  Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical c...